



UNITED STATES  
**NUCLEAR REGULATORY COMMISSION**  
REGION I  
475 ALLENDALE ROAD  
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

December 28, 2006

Docket No. 03007584  
Control No. 139775

License No. 37-06575-03

Patrick Alberts  
Chief Operating Officer  
Monongahela Valley Hospital, Inc.  
Country Club Road  
Monongahela, PA 15063

SUBJECT: MONONGAHELA VALLEY HOSPITAL, INC., LICENSE AMENDMENT,  
CONTROL NO. 139775

Dear Mr. Alberts:

This refers to your license amendment request dated December 6, 2006. Enclosed with this letter is the amended license.

Please note that a management representative should sign all future correspondence that requests a change in your license.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Current NRC regulations and guidance are included on the NRC's website at [www.nrc.gov](http://www.nrc.gov); select **Nuclear Materials; Medical, Academic, and Industrial Uses of Nuclear Material**; then **Toolkit Index Page**. Or you may obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-888-293-6498. The GPO is open from 7:00 a.m. to 8:00 p.m. EST, Monday through Friday (except Federal holidays).

Thank you for your cooperation.

Sincerely,

***Original signed by Shirley Xu***

Shirley Xu  
Health Physicist  
Medical Branch  
Division of Nuclear Materials Safety

P. Alberts  
Monongahela Valley Hospital, Inc.

2

Enclosure:  
Amendment No. 43

cc: Michael J. Semon, Radiation Safety Officer

DOCUMENT NAME: C:\FileNet\ML070030338.wpd

**SUNSI Review Complete: SXu**

After declaring this document "An Official Agency Record" it will be released to the Public.

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	<input checked="" type="checkbox"/> N	DNMS/RI	<input type="checkbox"/>	DNMS/RI	<input type="checkbox"/>	<input type="checkbox"/>
NAME	SXu /SSX/						
DATE	12/28/06						

OFFICIAL RECORD COPY

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Monongahela Valley Hospital, Inc.</p> <p>2. Country Club Road Monongahela, Pennsylvania 15063</p>	<p>In accordance with the letter dated December 6, 2006</p> <p>3. License number 37-06575-03 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date October 31, 2014</p> <hr/> <p>5. Docket No. 030-07584 Reference No.</p>
---	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.400</p> <p>E. Any byproduct material permitted by 10 CFR 31.11</p> <p>F. Cesium 137</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed sources as specified in condition 12</p> <p>E. Prepackaged Kits</p> <p>F. Sealed Sources (Compagnie ORIS Industrie Model CSM-3 series, distributed by CIS-US, Inc.)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 1000 millicuries</p> <p>D. 3000 millicuries</p> <p>E. 5 millicuries</p> <p>F. Not to exceed 150 millicuries per source and 1 curie total</p>
--	--	--

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300 for which the patient may be released under the provisions of 10 CFR 35.75

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
37-06575-03

Docket or Reference Number  
030-07584

Amendment No. 43

- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.  
E. In vitro studies.  
F. For possession and storage only.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at Country Club Road, Monongahela, Pennsylvania.  
11. The Radiation Safety Officer for this license is Michael J. Semon, M.S.

12.	<u>Isotope</u>	<u>Source Manufacturer</u>	<u>Model Number</u>
	I-125	Medi-Physics, Inc. or Amersham Health Amersham Health	6711/6733
	I-125	BEBIG	112.S06
	I-125	Best Medical International, Inc.	2301
	I-125	DRAXIMAGE, Inc.	LS-1
	I-125	Implant Sciences Corporation	3500
	I-125	International Brachytherapy SA	1251L
	I-125	IsoAid, L.L.C.	IAI-125A
	I-125	Mills Biopharmaceuticals, Inc.	I-125 SL/I-125 SH
	I-125	North American Scientific, Inc.	MED 3631
	I-125	Bard Brachytherapy, Inc.	STM1251
	I-125	Theragenics Corporation	I-Seed I25.S06
	Ir-192	Best Medical International, Inc.	81-01

13. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.  
B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Abdul S. Chaudry, M.D.	35.100; 35.200; 35.300; <u>In vitro</u> studies
Vinod N. Chablani, M.D.	35.100; 35.200; 35.300; <u>In vitro</u> studies
Douglas Wilson, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction; <u>In vitro</u> studies
M. Mohsin Rahman, M.D.	35.100; 35.200; 35.300

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
37-06575-03

Docket or Reference Number  
030-07584

Amendment No. 43

C. The following individuals are authorized users for non-medical uses as indicated.

Authorized Users

Material and Use

Michael J. Semon, M.S.

Cesium 137 (Possession and storage only)

14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
15. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
16. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 5 years from the date of each inventory and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
17. A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.
- B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
- C. Sealed sources need not be tested if they contain only hydrogen-3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.
- D. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
37-06575-03Docket or Reference Number  
030-07584

Amendment No. 43

- E. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.
- F. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
- G. Records of leak test results shall be kept in units of microcuries and shall be maintained for 5 years.
18. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
19. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated July 26, 2004 [ML042220301]  
B. Letter dated September 10, 2004 [ML042660502]  
C. Letter dated March 18, 2005 [ML051160300]  
D. Letter dated May 25, 2005 [ML051600025]

For the U.S. Nuclear Regulatory Commission

**Original signed by Shirley Xu**Date December 28, 2006

By

---

Shirley Xu  
Medical Branch  
Division of Nuclear Materials Safety  
Region I  
King of Prussia, Pennsylvania 19406